Expects to deliver three Investigational New Drug (IND) applications in next three years based on next-generation ADC technology -- Two new ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...

A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...

Good morning and welcome to Agenus' third quarter 2024 conference call and webcast. All participants will be in a listen-only ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

New results from a pooled analysis of patients will be featured in a late-breaking presentation at the upcoming European ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

(esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation ...

Check out some anticipated series in the video above or the slideshow gallery below, followed by the full list of new Fall season 2024 anime and where to watch them in the U.S. and their ...

Combination therapy with enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) was associated with durable responses and ...